Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Has Consensus Price Target of $98.56

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $98.56.

Several brokerages recently commented on ESTA. TD Cowen reaffirmed a “buy” rating and issued a $117.00 price objective on shares of Establishment Labs in a research report on Thursday. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research report on Thursday, August 6th. BTIG Research reissued a “buy” rating and set a $103.00 target price on shares of Establishment Labs in a research report on Tuesday, September 1st. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Finally, Stifel Nicolaus set a $85.00 price target on shares of Establishment Labs and gave the stock a “buy” rating in a report on Wednesday.

Establishment Labs Stock Performance

Establishment Labs stock opened at $59.18 on Friday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock has a market cap of $1.76 billion, a PE ratio of -45.18 and a beta of 1.06. The stock has a 50-day moving average of $69.29 and a two-hundred day moving average of $74.50. Establishment Labs has a one year low of $45.39 and a one year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. The business had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter in the previous year, the firm posted ($0.57) EPS. Establishment Labs’s revenue was up 31.7% on a year-over-year basis. On average, research analysts anticipate that Establishment Labs will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently made changes to their positions in ESTA. BlackRock Inc. purchased a new position in Establishment Labs in the 2nd quarter worth $135,752,000. William Blair Investment Management LLC acquired a new stake in Establishment Labs during the 2nd quarter worth about $61,273,000. Bank of America Corp DE acquired a new stake in Establishment Labs during the 2nd quarter worth about $52,176,000. Rice Hall James & Associates LLC acquired a new stake in Establishment Labs during the 2nd quarter worth about $48,134,000. Finally, Nantahala Capital Management LLC purchased a new stake in Establishment Labs during the 2nd quarter valued at about $28,817,572. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc (NASDAQ: ESTA) is a medical technology company focused on women’s health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets.